Moreover, another HRD1 substrate, p53 is decreased, which weaken the activation of the TP53-NM23H1/2 pathway, which consequently enhances the metastatic potential of NSCLC (Fig. 6, right panel). The gene discussed is TP53; the disease is non-small cell lung carcinoma.